Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:CLIK

Click Q2 2026 Earnings Report

Click logo
$1.41 -0.03 (-2.08%)
As of 04:00 PM Eastern
ProfileEarnings HistoryForecast

Click EPS Results

Actual EPS
$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Click Revenue Results

Actual Revenue
$3.79 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Click Announcement Details

Quarter
Q2 2026
Date
5/11/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Click Earnings Headlines

Clicks’ power keyboard brings BlackBerry-style typing to any phone — with some compromises
August 10 at 5:58 PM  |  msn.comhttps://www.msn.com/en-us/technology/consumer-electronics/clicks-power-keyboard-brings-blackberry-style-typing-to-any-phone-with-some-compromises/ar-AA29MQNs
I used the Clicks Power Keyboard for a week to see if it helped me type on my iPhone
August 5, 2026  |  cnn.comhttps://www.cnn.com/cnn-underscored/reviews/clicks-power-keyboard
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
August 12 at 1:00 AM  |  Stansberry Research (Ad)
The BlackBerry-inspired Clicks Communicator just got its first official case
July 31, 2026  |  msn.comhttps://www.msn.com/en-us/technology/consumer-electronics/the-blackberry-inspired-clicks-communicator-just-got-its-first-official-case/ar-AA298JPz
Click Holdings’ Logistics Arm Powers Care U Expansion and Planned Spin-Off
July 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/click-holdings-logistics-arm-powers-care-u-expansion-and-planned-spin-off?utm_source=marketbeat.com&utm_medium=referral
Logistics Division Hyper-Growth (+80% CAGR) Unlocks Multi-Year Run Rate — Accelerating CLIK's High-Margin Care U Expansion & Strategic Spin-Off
July 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/21/3330410/0/en/logistics-division-hyper-growth-80-cagr-unlocks-multi-year-run-rate-accelerating-clik-s-high-margin-care-u-expansion-strategic-spin-off.html
See More Click Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Click? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Click and other key companies, straight to your email.

About Click

Click (NASDAQ:CLIK) Therapeutics, Inc. (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review. Several of its lead digital therapeutics have earned Breakthrough Device designation from the U.S. Food and Drug Administration and have pursued CE marking for commercialization in Europe. The company collaborates with pharmaceutical partners, academic institutions and healthcare providers to integrate its digital products into clinical pathways and to collect real-world evidence supporting safety and efficacy.

Headquartered in New York City, Click operates in the United States with strategic alliances in select international markets. Its leadership team draws on deep experience in digital health innovation, neuroscience research and pharmaceutical development. Click continues to invest in research and development, aiming to expand its pipeline into new therapeutic areas and to scale adoption of its digital therapeutics globally.

View Click Profile
Earnings Tools